A booster shot approval study of AKS-452 (AmbiVax-C)
Latest Information Update: 21 Mar 2022
At a glance
- Drugs AKS-452 (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
Most Recent Events
- 21 Mar 2022 New trial record